HR and breast cancer: BC is classified into four clinical subtypes based on the expression of human epidermal growth factor 2 (HER2), hormone receptors (HR), and progesterone receptor (PR): Luminal A, Luminal B, HER2-positive, and TNBC (Hung et al, 2023).